Incyte Corp. (INCY)

From the record

Incyte Corp.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Incyte Corp.'s 9 filed years say what it did: revenue went from $1.5 billion in fiscal 2017 to $5.1 billion in fiscal 2025, up 16.3% a year; it rose in 8 of 8 years; it never fell from a peak; net income was positive in 7 of 9 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Incyte Corp.'s diluted share count shrank about 3.6% a year, and dividends and buybacks returned about 89% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 49 sales (49 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-10 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Incyte Corp. earned about 25 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 69 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 26 cents per dollar of assets, and net share issuance: its share count shrank 4.7% over the year (the filed statements).

From the record

Incyte Corp.'s standing among 12 graded names in its industry family: revenue of $5.1 billion in fiscal 2025 ranks in the top 21% by size; a net margin of 25% ranks in the top 4%; revenue growth of 14.8% a year over the last 3 filed years ranks in the top 21% (its annual reports).

From the record

Incyte Corp.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Meury, William (Chief Executive Officer, as filed), filing under that title since 2025-06-30, 1.4 years (bottom 36% of its family); the 23 officers and directors filing in the last fifteen months have been on the record a median of 4.6 years (bottom 31%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 23 people in charge now (top 50%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Incyte Corp.'s room to grow, from the newest filed statements (fiscal 2025): cash of $3.1 billion against no long-term debt tagged leaves 44.5% of its assets as net cash, top 21% of its family; cash from operations less capital spending is 27.5% of revenue (top 4%); a gross margin of 92.8% (top 12%); research spending of 39.9% of revenue (bottom 25%) (its annual report).

From the record

Incyte Corp.'s growth drivers, from the filed years to fiscal 2025: revenue grew 14.8% a year over the last three filed years against 16.3% over all 9, slowing (top 29% of its family); the newest year grew 21.2% (top 12%); research spending grew 8.9% a year (top 31%); capital spending grew -0.1% a year (top 21%) (its annual reports). Incyte Corp. reported 12 product lines in fiscal 2025: JAKAFI at $3.1 billion (60%), OPZELURA at $678 million (13%), JAKAVI Royalty Revenues at $458 million (9%), and 9 more; 11 of 11 grew against the year before (its annual report).

From the record

Incyte Corp.'s newest year against its own record: revenue of $5.1 billion in fiscal 2025 came in 8.5% above the $4.7 billion its prior three years' pace pointed to (top 14% of its family); net income of $1.3 billion against a prior three-year average of $324 million (top 5%); a net margin of 25% against 9% before (top 23%) (its annual reports).